SCHEMBL18486268

SCHEMBL18486268

CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H]2O[Si](C(C)(C)C)(C(C)(C)C)OC[C@H]2O[C@H]1n1cnc2c(-c3cccc(C=O)c3)ncnc21

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ DNPH1 O43598 15/20 0.37
▸ STING1 Q86WV6 1/20 0.33
▸ CYP1A2 P05177 1/20 0.30
▸ HTR1A P08908 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ ADRB3 P13945 1/20 0.30
▸ PDE4A P27815 1/20 0.30
▸ PTGS2 P35354 1/20 0.30
▸ PDE4D Q08499 1/20 0.30
▸ PDE3A Q14432 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16871895 0.90 DNPH1 (0.44) DNPH1STING1PDE4APDE4D
SCHEMBL17363663 0.90 DNPH1 (0.44) DNPH1STING1PDE4APDE4D
SCHEMBL17363867 0.89 DNPH1 (0.37) DNPH1STING1
SCHEMBL17363656 0.89 DNPH1 (0.37) DNPH1STING1
SCHEMBL16871738 0.89 DNPH1 (0.37) DNPH1STING1
SCHEMBL17363657 0.89 DNPH1 (0.37) DNPH1STING1
SCHEMBL18486390 0.88 DNPH1 (0.49) DNPH1STING1
SCHEMBL16871801 0.86 DNPH1 (0.45) DNPH1STING1
SCHEMBL17363530 0.86 DNPH1 (0.45) DNPH1STING1
SCHEMBL18486312 0.86 DNPH1 (0.35) DNPH1STING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 — — EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 — — US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 — — US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 DNPH1 2051/4885STING1 1024/4885CYP1A2 1890/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 DNPH1 2035/4885STING1 1050/4885CYP1A2 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback